ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1383	National Cancer Institute	Html	en	Primary CNS Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of primary CNS lymphoma.	neurologic toxic effects 0.298255 phase II study 0.301181 Median survival times 0.290496 autologous stem-cell transplantation 0.303999 intraocular lymphoma 0.357403 Int J Radiat 0.280843 multicenter trial 0.337891 high-dose chemotherapy 0.457349 Radiat Oncol Biol 0.35284 newly diagnosed patients 0.281995 median overall survival 0.288155 median OS 0.305882 oncology group study 0.287293 Median progression-free survival 0.289876 patients 0.38833 hematopoietic stem-cell rescue 0.299776 intensive chemotherapy 0.334942 refractory CNS lymphoma 0.401669 recurrent primary CNS 0.355753 Enhanced Chemotherapy Delivery 0.290362 immunodeficiency syndrome-related lymphoma 0.3182 radiation therapy 0.416652 radiotherapy 0.304692 high-dose cytarabine 0.339318	Ferreri AJ 0.299732 et al. 0.375948 brief single-agent methotrexate 0.293099 Non-AIDS Primary CNS 0.32387 intrathecal methotrexate 0.298746 PUBMED Abstract 0.333438 median time-to-treatment failure 0.282021 primary cns lymphoma 0.672691 median follow-up 0.314518 intraventricular methotrexate 0.280851 autologous stem cell 0.35468 radiation therapy oncology 0.371114 Abstract 0.508209 Clin Oncol 0.757019 Oncol Biol Phys 0.354909 high-dose methotrexate-based chemotherapy 0.379055 primary brain lymphoma 0.340924 Lymphoma Group Phase 0.33918 high-dose methotrexate-based therapy 0.321219 nervous system lymphoma 0.614476 primary cns 0.932952 therapy oncology group 0.373019 DeAngelis LM 0.317758 high-dose methotrexate 0.643572	CLICK HERE
1592	National Cancer Institute	Html	en	Thymoma and Thymic Carcinoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of thymoma and thymic carcinoma.	cancer treatment 0.359999 malignant tumor cells 0.342024 body 0.355156 type 0.305883 PDQ cancer information 0.433839 clinical trial search 0.425022 cancer cell 0.325256 thymic carcinoma cells 0.326827 clinical trials 0.988832 thymoma 0.371455 cancer information summary 0.383363 clinical trial 0.804071 patients 0.340124 earlier clinical trials 0.306378 thymic carcinoma spreads 0.306453 treatment clinical trial 0.327343 PDQ Adult Treatment 0.30754 NCI PDQ cancer 0.333099 radiation therapy 0.826788 Treatment Editorial Board 0.331284 thymic carcinomas 0.308782 General information 0.310597 general cancer information 0.312288 thymic carcinoma 0.970766 treatment 0.610928	new ways 0.369751 anticancer drugs 0.338472 new cancer treatments 0.318168 NCI-supported cancer 0.344007 cancer cells 0.453663 Cancer Information Service 0.312701 treatment clinical trials 0.363023 thymic carcinoma look 0.319623 National Cancer Institute 0.457133 tumor cells 0.34225 normal cells 0.313543 new treatment 0.393453 new combinations 0.333745 Blood. The cancer 0.306577 metastatic tumor 0.308755 PDQ summary 0.316304 cancer clinical trials 0.447345 stage 0.3338 tumor 0.364487 cancer information summaries 0.310618 comprehensive cancer information 0.311036 Thymic Carcinoma Treatment 0.323064 cancer 0.980046 standard treatment 0.319507	CLICK HERE
1639	National Cancer Institute	Html	en	Laetrile/Amygdalin (PDQ®)–Patient Version	Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer.	cancer treatment 0.438388 cervical cancer cells 0.371507 PDQ cancer information 0.581258 Cancer Complementary 0.379362 clinical trials 0.679597 cancer information summary 0.498013 alternative cancer therapies 0.390365 prostate cancer cells 0.371683 CAM cancer research 0.368282 patented Laetrile 0.633733 stomach cancer patient 0.364287 patients 0.536772 cancer patients 0.418354 NCI PDQ cancer 0.43909 cancer information database 0.387329 colon cancer cells 0.371605 Therapies Editorial Board 0.387373 metabolic therapy program 0.390038 cancer cell blockers 0.374799 cancer information 0.599008 intravenous Laetrile 0.592397 laboratory study 0.361622 cancer prevention 0.356496 United States 0.577981	Complementary Therapies Editorial 0.420338 Drug Administration 0.401022 Cancer Information Specialist 0.378718 cancer cells 0.467012 Cancer Information Service 0.494306 laetrile breaks 0.600513 chemical amygdalin 0.44529 tumor size 0.381862 treatment clinical trials 0.357955 National Cancer Institute 0.807094 studies 0.358599 laetrile treatment 0.698121 alternative medicine 0.450551 amygdalin therapy 0.422594 Federal Trade Commission 0.354832 new treatment 0.383104 amygdalin 0.621984 Cancer Care page 0.354541 case reports 0.418082 alternative therapies 0.420918 hydrogen cyanide 0.363445 cancer information summaries 0.388577 laetrile 0.967938 cancer 0.903387	CLICK HERE
1652	National Cancer Institute	Html	en	PC-SPES (PDQ®)–Patient Version	Expert-reviewed information summary about the use of PC-SPES as a treatment for prostate cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.437115 cancer prevention 0.282542 Complementary Therapies Editorial 0.411772 United States 0.349637 Drug Administration 0.423619 Cancer Information Specialist 0.306354 PC-SPES 0.776503 Cancer Information Service 0.45748 PDQ cancer information 0.587454 Cancer Complementary 0.346119 CAM therapies 0.322693 treatment clinical trials 0.274541 National Cancer Institute 0.691988 clinical trials 0.701375 alternative medicine 0.539683 PC-SPES lowers PSA 0.309751 U.S. Food 0.291013 conventional treatment 0.269047 health care 0.271323 cancer information summary 0.466619 alternative cancer therapies 0.329832 Federal Trade Commission 0.302224 National Institutes 0.284819 cancer cells 0.400978	clinical trial 0.31949 National Center 0.264606 prostate cancer cells 0.342551 CAM cancer research 0.300048 breast cancer prevention 0.277639 cancer patients 0.279371 Cancer Care page 0.279808 prostate specific antigen 0.386617 traditional Chinese medicine 0.370287 health 0.346702 NCI’s PDQ 0.273024 PDQ summary 0.278148 Integrative Health 0.265541 NCI PDQ cancer 0.391945 cancer information database 0.323738 prostate cancer 0.519752 effects 0.26747 prescription medicines 0.565306 alternative therapies 0.390035 cancer information summaries 0.324417 Therapies Editorial Board 0.356431 cancer 0.944963 prostate problems 0.265671	CLICK HERE
1879	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) en el embarazo (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) en el embarazo.	Chua T 0.308433 Rugo HS 0.308741 exposed to chemotherapy 0.30311 Surg Gynecol Obstet 0.330452 outcome after 0.304299 pregnant patient 0.315879 anomalías congénitas 0.308598 Clark RM 0.307911 Theriault R 0.32478 cancer diagnosed during 0.342035 diagnosed during pregnancy 0.34332 Loprinzi CL 0.304379 Sin embargo 0.313532 patient with carcinoma 0.318411 mother during gestation 0.303218 Instituto Nacional 0.305213 Petrek JA 0.304025 Yang WT 0.304051 breast carcinoma during 0.308603 breast carcinoma 0.313568 Gynecol Oncol 0.302701 altas concentraciones 0.304242 cancer diagnosed 0.35036 safety after breast 0.308046 chemotherapy during pregnancy 0.3192	Curr Treat Options 0.317342 administration during pregnancy 0.307821 overall survival after 0.302827 R Coll Radiol 0.316078 Wallack MK 0.309132 Gallenberg MM 0.304139 ultimate challenge 0.308285 Surg Clin North 0.303453 National Cancer Institute 0.306047 during pregnancy 0.532041 Surg Oncol 0.303192 pregnant patient with 0.318156 PDQ Tratamiento 0.303689 after maternal cancer 0.306691 Clin Oncol 0.325015 Radiotherapy during pregnancy 0.307723 breast cancer 0.976679 systematic review 0.303372 Treat Options Oncol 0.318121 Dryden MJ 0.304024 breast cancers from 0.308506 with or without 0.302892 as systemic treatment 0.302539 Gwyn K 0.36898	CLICK HERE
1947	National Cancer Institute	Html	es	Tratamiento del cáncer de laringe (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de laringe.	glándula tiroides 0.639428 Hemilaringectomía cirugía 0.60821 Neck Cancer 0.605848 siguientes procedimientos 0.707332 laringectomía parcial ayuda 0.615346 estadio ii 0.651257 rayos x 0.611158 pequeñas marcas 0.606254 estadio ivb 0.616957 estadio ivc 0.633063 enlace drugs approved 0.610885 tratado.ampliar radioterapia 0.630743 órgano fonador 0.612088	National Cancer Institute 0.602872 siguientes riesgos 0.602157 malla ayuda 0.606514 Instituto Nacional 0.606325 PDQ Tratamiento 0.606553 presente sección 0.60533 Physician Data Query 0.613617 haz angosto 0.606683 ganglio linfático mide 0.979756 laringe dónde 0.67158 paciente respire 0.60867 siguientes estadios 0.629924	CLICK HERE
1977	National Cancer Institute	Html	es	Tratamiento del carcinoma de corteza suprarrenal (PDQ®)–Versión para pacientes	Resumen de revisión revisada por expertos acerca del tratamiento del carcinoma de corteza suprarrenal.	siguientes procedimientos 0.496457 tinte circula 0.500083 pequeña cantidad 0.426407 estadio ii 0.722852 vía oral 0.42258 rayos x 0.485722 ondas sonoras 0.428325 National Cancer Institute 0.418399 sustancia llamada gadolinio 0.451231 suprarrenal elabora hormonas 0.951617 siguientes riesgos 0.416128 secciones cáncer 0.564083 Instituto Nacional 0.51582 PDQ Tratamiento 0.443801 siguientes hormonas 0.456613	presente sección 0.419609 corteza suprarrenal causa 0.829807 siguientes funciones 0.454626 Physician Data Query 0.471125 médula suprarrenal.Ampliar 0.44071 estadio iii 0.71977 características masculinas 0.438548 siguientes enfermedades 0.449744 PDQ Feocromocitoma 0.493816 suprarrenal causa efectos 0.739636 siguientes terapias 0.423482 PDQ Cánceres 0.484481 siguientes enlaces 0.420507 suprarrenal funcionante elabora 0.710246 siguientes pruebas 0.503631	CLICK HERE
2988	National Cancer Institute	Html	en	Secondhand Smoke	Smoking affects both you and your loved one's health. Learn about the consequences of secondhand smoke and how you can protect your family.	feet 0.409991 dangers 0.420271 Lung cancer 0.428942 good example 0.428021 non-smoker 0.407426 care staff 0.426607 nicotine affect 0.427281 babysitters 0.406286 body 0.411562 smoker 0.414092 children 0.431937 harms 0.407652 sure caretakers 0.428123 secondhand smoke 0.971613 non-smokers 0.43912 heart disease‚ 0.429635 Fact 0.410452 short time 0.429909 somebody 0.406088 health problems 0.428728 smokefree restaurants 0.432863 lung infections 0.428228 smoking indoors 0.445671 main way smoking 0.477206 Breathing problems 0.428866	indoor public places 0.450365 babies 0.424287 smokers 0.419121 air 0.417572 life 0.412446 Breathing secondhand smoke 0.5983 infant death syndrome 0.453829 smoking 0.508887 National Cancer Institute 0.448359 heart attack‚ 0.429618 kids 0.411336 quiz 0.411311 cigarette 0.405834 coughing‚ extra phlegm‚ 0.454984 bronchitis 0.405901 people 0.432125 home 0.416331 nannies 0.405803 severe attacks 0.428972 best thing 0.428251 shortness 0.406847 ear infections 0.428442 low birth weight 0.454001 family 0.425482	CLICK HERE
16645	National Cancer Institute	Html	en	Understanding “Chemobrain” and Cognitive Impairment after Cancer Treatment	An NCI research update about research to investigate what factors play a role in “chemobrain” or cognitive impairment after cancer treatment.	cognitive problems 0.439925 cognitive behavioral therapy 0.339182 cancer treatment 0.685512 cognitive effects 0.256058 self-reported cognitive functioning 0.391696 lower cognitive performance 0.348528 cognitive decline 0.284161 chemotherapy 0.377855 long-term cognitive changes 0.331518 chemotherapy treatment 0.254041 cognitive challenges 0.286627 cognitive issues 0.282189 Kettering Cancer Center 0.246129 chemotherapy-associated cognitive impairment 0.369163 Wilmot Cancer Institute 0.218061 Dr. Ganz 0.536508 Jonsson Comprehensive Cancer 0.230946	Dr. Ahles 0.527642 cognitive rehabilitation program 0.323502 cognitive changes 0.469428 healthy women 0.234218 breast cancer patients 0.251612 recent research 0.354647 patients 0.34223 Cancer Therapy-Cognitive Function 0.218486 breast cancer survivors 0.783509 cognitive difficulties 0.366868 treatment-related cognitive impairment 0.464189 hormonal therapy 0.233078 self-reported cognitive complaints 0.381226 cognitive symptoms 0.25427 cognitive impairment 0.941275 neuropsychological tests 0.263188	CLICK HERE
16837	National Cancer Institute	Html	en	Stanford University — Cancer Translational Nanotechnology Training Program	The focus of the Stanford University Cancer Nanotechnology Training Center is presented here.	interdisciplinary leaders 0.696815 program director 0.689314 nanoengineering 0.558309 M.D. 0.531791 molecular imaging 0.829201 faculty 0.529401 3-year program 0.755923 proposed 5-year cycle 0.860016 Ph.D. 0.531868 skill sets 0.677497 trainee progress 0.671123 Stanford Cancer-Translational Nanotechnology 0.898203 cancer immunology 0.705615 molecular pharmacology 0.687504 gene therapy 0.664625 cross-disciplinary training 0.726482 complementary mentors 0.683687 coursework 0.53863 biochips 0.551532 Stanford CNTC website 0.833637 interdisciplinary researchers 0.692233 molecular biology 0.695814 Jianghong Rao 0.719515 electrical engineering 0.669775	grant application process 0.806404 cancer research 0.843254 research advisor 0.68327 Advisory Committee 0.662141 Stanford Oncology Clinical 0.845549 National Cancer Institute 0.835301 Principal Investigator 0.706879 postdoctoral trainees 0.850619 Dean Felsher 0.699264 Training Committee 0.688222 clinical translation 0.702935 materials science 0.66948 nanomedicine 0.549348 3-year training program 0.964337 hands-on training activities 0.833884 clinical component 0.680058 bioengineering 0.539755 cancer nanotechnology translation 0.891967 Lecture Series 0.660584 clinical cancer medicine 0.877908 entire program 0.674038 Training Focus 0.735031 cancer biology 0.706458 mock grant proposal 0.812529	CLICK HERE